Carisma Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2011
Net Income	-81.22	-86.88	-61.23	-0.34	-22.54	-107.5	Upgrade
Depreciation & Amortization	9.28	8.27	6.09	0.09	0.12	0.22	Upgrade
Share-Based Compensation	3.11	2.32	0.28	5.14	1.76	1.24	Upgrade
Other Operating Activities	-9.25	-4.88	49.75	-73.77	-10.32	68.52	Upgrade
Operating Cash Flow	-78.07	-81.18	-5.12	-68.88	-30.84	-37.52	Upgrade
Capital Expenditures	-1.01	-1.13	-4.66	-0	-0.01	-0.14	Upgrade
Change in Investments	77	73.54	-27.9	0	0	0	Upgrade
Investing Cash Flow	75.99	72.41	-32.56	-0	-0.01	-0.14	Upgrade
Share Issuance / Repurchase	3.07	31.42	0.11	176.13	38.1	35.35	Upgrade
Debt Issued / Paid	-3.21	-1.33	33.21	0	0	0	Upgrade
Other Financing Activities	-4.07	32.09	-	-0	0.01	0.01	Upgrade
Financing Cash Flow	-4.21	62.18	33.32	176.13	38.11	35.36	Upgrade
Net Cash Flow	-6.29	53.41	-4.36	107.25	7.27	-2.3	Upgrade
Free Cash Flow	-79.08	-82.31	-9.78	-68.88	-30.85	-37.66	Upgrade
Free Cash Flow Margin	-524.66%	-551.71%	-99.41%	-259.50%	-274.52%	-	Upgrade
Free Cash Flow Per Share	-1.93	-2.46	-4.59	-7.56	-5.22	-8.28	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).